Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
NUTX vs THC vs HCA vs CYH vs UHS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
NUTX vs THC vs HCA vs CYH vs UHS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $814M | $16.68B | $97.29B | $393M | $10.64B |
| Revenue (TTM) | $880M | $21.45B | $75.60B | $21.48B | $17.76B |
| Net Income (TTM) | $96M | $1.70B | $6.78B | $-88M | $1.52B |
| Gross Margin | 47.5% | 42.8% | 41.5% | 53.7% | 67.6% |
| Operating Margin | 31.4% | 16.1% | 15.8% | -39.8% | 11.5% |
| Forward P/E | 6.5x | 10.7x | 14.4x | 0.7x | 7.3x |
| Total Debt | $351M | $13.17B | $50.20B | $11.58B | $5.51B |
| Cash & Equiv. | $186M | $2.88B | $1.04B | $260M | $138M |
NUTX vs THC vs HCA vs CYH vs UHS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Nutex Health, Inc. (NUTX) | 100 | 9.7 | -90.3% |
| Tenet Healthcare Co… (THC) | 100 | 262.6 | +162.6% |
| HCA Healthcare, Inc. (HCA) | 100 | 202.8 | +102.8% |
| Community Health Sy… (CYH) | 100 | 36.4 | -63.6% |
| Universal Health Se… (UHS) | 100 | 138.7 | +38.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NUTX vs THC vs HCA vs CYH vs UHS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NUTX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 82.4%, EPS growth 7.9%, 3Y rev CAGR 58.6%
- 82.4% revenue growth vs CYH's -1.2%
- 11.0% margin vs CYH's -0.4%
THC ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 5.1% 10Y total return vs HCA's 457.9%
- PEG 0.32 vs HCA's 0.68
- +27.7% vs CYH's -17.7%
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.31, yield 0.7%
- Beta 0.31, yield 0.7%, current ratio 0.83x
- Beta 0.31 vs NUTX's 2.10
- 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend)
CYH is the clearest fit if your priority is value.
- Lower P/E (0.7x vs 7.3x)
UHS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.62, Low D/E 74.3%, current ratio 1.05x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 82.4% revenue growth vs CYH's -1.2% | |
| Value | Lower P/E (0.7x vs 7.3x) | |
| Quality / Margins | 11.0% margin vs CYH's -0.4% | |
| Stability / Safety | Beta 0.31 vs NUTX's 2.10 | |
| Dividends | 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.7% vs CYH's -17.7% | |
| Efficiency (ROA) | 11.3% ROA vs CYH's -0.7%, ROIC 19.9% vs -70.1% |
NUTX vs THC vs HCA vs CYH vs UHS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NUTX vs THC vs HCA vs CYH vs UHS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NUTX leads in 2 of 6 categories
HCA leads 2 • CYH leads 1 • THC leads 1 • UHS leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
NUTX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 85.9x NUTX's $880M. NUTX is the more profitable business, keeping 11.0% of every revenue dollar as net income compared to CYH's -0.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $880M | $21.5B | $75.6B | $21.5B | $17.8B |
| EBITDAEarnings before interest/tax | $297M | $4.3B | $15.5B | -$7.8B | $2.7B |
| Net IncomeAfter-tax profit | $96M | $1.7B | $6.8B | -$88M | $1.5B |
| Free Cash FlowCash after capex | $270M | $3.3B | $7.7B | -$200M | $894M |
| Gross MarginGross profit ÷ Revenue | +47.5% | +42.8% | +41.5% | +53.7% | +67.6% |
| Operating MarginEBIT ÷ Revenue | +31.4% | +16.1% | +15.8% | -39.8% | +11.5% |
| Net MarginNet income ÷ Revenue | +11.0% | +7.9% | +9.0% | -0.4% | +8.6% |
| FCF MarginFCF ÷ Revenue | +30.7% | +15.6% | +10.2% | -0.9% | +5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +2.8% | +6.7% | +2.8% | +9.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +154.7% | +87.6% | +44.6% | -45.2% | +17.7% |
Valuation Metrics
CYH leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 0.7x trailing earnings, CYH trades at a 95% valuation discount to HCA's 15.3x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.37x vs HCA's 0.73x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $814M | $16.7B | $97.3B | $393M | $10.6B |
| Enterprise ValueMkt cap + debt − cash | $980M | $27.0B | $146.5B | $11.7B | $16.0B |
| Trailing P/EPrice ÷ TTM EPS | 13.04x | 12.29x | 15.33x | 0.74x | 7.36x |
| Forward P/EPrice ÷ next-FY EPS est. | 6.50x | 10.65x | 14.40x | — | 7.27x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.37x | 0.73x | — | 0.46x |
| EV / EBITDAEnterprise value multiple | 3.31x | 6.27x | 9.46x | — | 6.13x |
| Price / SalesMarket cap ÷ Revenue | 0.93x | 0.78x | 1.29x | 0.03x | 0.61x |
| Price / BookPrice ÷ Book value/share | 2.18x | 1.93x | — | — | 1.48x |
| Price / FCFMarket cap ÷ FCF | 3.31x | 6.59x | 12.65x | 1.89x | 12.53x |
Profitability & Efficiency
NUTX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
NUTX delivers a 22.2% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $20 for THC. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), NUTX scores 7/9 vs UHS's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +22.2% | +19.6% | — | — | +20.7% |
| ROA (TTM)Return on assets | +10.5% | +5.7% | +11.3% | -0.7% | +9.8% |
| ROICReturn on invested capital | +38.0% | +13.2% | +19.9% | -70.1% | +12.3% |
| ROCEReturn on capital employed | +43.2% | +13.8% | +27.0% | -87.3% | +16.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 7 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.83x | 1.47x | — | — | 0.74x |
| Net DebtTotal debt minus cash | $166M | $10.3B | $49.2B | $11.3B | $5.4B |
| Cash & Equiv.Liquid assets | $186M | $2.9B | $1.0B | $260M | $138M |
| Total DebtShort + long-term debt | $351M | $13.2B | $50.2B | $11.6B | $5.5B |
| Interest CoverageEBIT ÷ Interest expense | 9.13x | 4.28x | 5.37x | 4.89x | 10.92x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,325 today (with dividends reinvested), compared to $228 for NUTX. Over the past 12 months, THC leads with a +27.7% total return vs CYH's -17.7%. The 3-year compound annual growth rate (CAGR) favors THC at 39.8% vs CYH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.8% | -4.5% | -7.3% | -10.0% | -22.6% |
| 1-Year ReturnPast 12 months | +13.2% | +27.7% | +23.8% | -17.7% | -7.1% |
| 3-Year ReturnCumulative with dividends | +77.5% | +173.1% | +59.6% | -19.8% | +20.4% |
| 5-Year ReturnCumulative with dividends | -97.7% | +193.3% | +111.2% | -80.8% | +10.8% |
| 10-Year ReturnCumulative with dividends | -97.7% | +511.4% | +457.9% | -81.0% | +30.3% |
| CAGR (3Y)Annualised 3-year return | +21.1% | +39.8% | +16.9% | -7.1% | +6.4% |
Risk & Volatility
HCA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than NUTX's 2.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCA currently trades 78.2% from its 52-week high vs CYH's 62.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.10x | 0.74x | 0.31x | 1.57x | 0.62x |
| 52-Week HighHighest price in past year | $193.07 | $247.21 | $556.52 | $4.47 | $246.33 |
| 52-Week LowLowest price in past year | $77.21 | $146.60 | $330.00 | $2.38 | $152.33 |
| % of 52W HighCurrent price vs 52-week peak | +70.8% | +77.0% | +78.2% | +62.4% | +69.0% |
| RSI (14)Momentum oscillator 0–100 | 61.5 | 52.6 | 30.7 | 47.7 | 42.6 |
| Avg Volume (50D)Average daily shares traded | 194K | 1.2M | 1.0M | 1.6M | 777K |
Analyst Outlook
HCA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NUTX as "Buy", THC as "Buy", HCA as "Buy", CYH as "Hold", UHS as "Hold". Consensus price targets imply 50.0% upside for NUTX (target: $205) vs 5.0% for CYH (target: $3). For income investors, HCA offers the higher dividend yield at 0.68% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $205.00 | $259.50 | $527.45 | $2.93 | $226.00 |
| # AnalystsCovering analysts | 2 | 32 | 46 | 37 | 43 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.7% | — | +0.5% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 5 | 2 | 1 |
| Dividend / ShareAnnual DPS | — | — | $2.94 | — | $0.80 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +8.6% | +10.3% | +0.5% | +9.1% |
NUTX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HCA leads in 2 (Risk & Volatility, Analyst Outlook).
NUTX vs THC vs HCA vs CYH vs UHS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NUTX or THC or HCA or CYH or UHS a better buy right now?
For growth investors, Nutex Health, Inc.
(NUTX) is the stronger pick with 82. 4% revenue growth year-over-year, versus -1. 2% for Community Health Systems, Inc. (CYH). Community Health Systems, Inc. (CYH) offers the better valuation at 0. 7x trailing P/E, making it the more compelling value choice. Analysts rate Nutex Health, Inc. (NUTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NUTX or THC or HCA or CYH or UHS?
On trailing P/E, Community Health Systems, Inc.
(CYH) is the cheapest at 0. 7x versus HCA Healthcare, Inc. at 15. 3x. On forward P/E, Nutex Health, Inc. is actually cheaper at 6. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 32x versus HCA Healthcare, Inc. 's 0. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NUTX or THC or HCA or CYH or UHS?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +193.
3%, compared to -97. 7% for Nutex Health, Inc. (NUTX). Over 10 years, the gap is even starker: THC returned +511. 4% versus NUTX's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NUTX or THC or HCA or CYH or UHS?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 31β versus Nutex Health, Inc. 's 2. 10β — meaning NUTX is approximately 583% more volatile than HCA relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — NUTX or THC or HCA or CYH or UHS?
By revenue growth (latest reported year), Nutex Health, Inc.
(NUTX) is pulling ahead at 82. 4% versus -1. 2% for Community Health Systems, Inc. (CYH). On earnings-per-share growth, the picture is similar: Community Health Systems, Inc. grew EPS 196. 7% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, NUTX leads at 58. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NUTX or THC or HCA or CYH or UHS?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 4. 1% for Community Health Systems, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUTX leads at 31. 5% versus -79. 4% for CYH. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NUTX or THC or HCA or CYH or UHS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 32x versus HCA Healthcare, Inc. 's 0. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Nutex Health, Inc. (NUTX) trades at 6. 5x forward P/E versus 14. 4x for HCA Healthcare, Inc. — 7. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUTX: 50. 0% to $205. 00.
08Which pays a better dividend — NUTX or THC or HCA or CYH or UHS?
In this comparison, HCA (0.
7% yield), UHS (0. 5% yield) pay a dividend. NUTX, THC, CYH do not pay a meaningful dividend and should not be held primarily for income.
09Is NUTX or THC or HCA or CYH or UHS better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31), 0. 7% yield, +457. 9% 10Y return). Nutex Health, Inc. (NUTX) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +457. 9%, NUTX: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NUTX and THC and HCA and CYH and UHS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NUTX is a small-cap high-growth stock; THC is a mid-cap deep-value stock; HCA is a mid-cap deep-value stock; CYH is a small-cap deep-value stock; UHS is a mid-cap deep-value stock. HCA pays a dividend while NUTX, THC, CYH, UHS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.